Zobrazeno 81 - 90
of 186
pro vyhledávání: ''
Publikováno v:
Cancer Research. 76:1253-1253
Lung cancer remains the leading cause of cancer related mortality throughout the world, and is estimated to kill more than one million people this year. Mutations in KRAS occur in about 1/3 of all lung adenocarcinomas, the most common histologic subt
Autor:
Jeffrey Norris, Regan M. Memmott, Kristin J. Lastwika, Phillip A. Dennis, Joell J. Gills, Krista Pearman
Publikováno v:
Cancer Research. 76:4330-4330
Lung cancer is the leading cause of cancer-related mortality worldwide, and 85% of lung cancer cases are associated with tobacco use. Within this group, activating mutations in K-ras have been identified in ∼25% of lung adenocarcinomas. Using a mou
Autor:
Shinichi Chiba, Naoyuki Miyokawa, Takaaki Sasaki, Shunsuke Okumura, Masatoshi Sado, Yoshinobu Ohsaki, Hiroshi Funakoshi
Publikováno v:
Cancer Research. 76:2267-2267
[Background] Biomarkers like epidermal growth factor receptor (EGFR) gene mutations or anaplastic lymphoma kinase (ALK) rearrangement have been discovered in lung cancer, leading to targeted therapies developed in non-small cell lung cancer (NSCLC).
Autor:
Yongchang Zhang
Publikováno v:
Cancer Research. 76:2262-2262
Background: Deregulating cellular energetics is one promising hallmark of cancer and Thioredoxin reductases 1 (TrxR1) plays a key role in cell metabolism [1-4]. It was found in our previous study that the activity of TrxR1 in serum is significantly h
Autor:
Cécile Jovelet, David Planchard, Chloe Pannet, Emma Green, Nitzan Rosenfeld, Ludovic Lacroix, Ken Oulassen, Andrew R. J. Lawson, Sarah Smalley, Vincent Plagnol, Nathalie Chaput, Jordi Remon, Benjamin Besse, David Gale, Kenth Howarth, A. Gazzah, Jean-Charles Soria
Publikováno v:
Cancer Research. 76:3192-3192
Introduction: Approximately 30% of patients with an adenocarcinoma of the lung have an actionable driver mutation. Further understanding the molecular mechanisms of acquired resistance to targeted therapies provides key information for determining su
Autor:
Timothy G. Whitsett, Kelley O’Brien, Landon J. Inge, Amanda L. Richer, Jacqueline M. Cala, Vashti M. Carson
Publikováno v:
Cancer Research. 76:2817-2817
Within eukaryotic cells, the G1/S and G2/M cell cycle checkpoints activate in response to intracellular or extracellular stress to prevent defects in DNA synthesis and mitosis. Deregulation of the cell cycle is a fundamental characteristic of cancer,
Autor:
Luiza Madia Lourenco, Fiona Cahill, Sivan M. Bokobza, Yanyan Jiang, Anika M. Weber, Nuramalina H. Mumin, Thomas M. Ashton, Aoife M. Devery, Anderson J. Ryan, Neele Drobnitzky
Publikováno v:
Molecular Cancer Therapeutics. 14:C114-C114
Lung cancer is the leading cause of cancer related death worldwide and adenocarcinoma is the most prevalent subtype. LKB1 (STK11) is the second most commonly altered tumour suppressor in adenocarcinoma and is inactivated in 17% of samples (1). LKB1 i
Autor:
Yana Raeva, Cordula Tschuch, Kerstin Klingner, Anne Löhr, Eva Oswald, Anne-Lise Peille, Julia Schüler, Dorothee Lehnhard
Publikováno v:
Molecular Cancer Therapeutics. 14:A10-A10
Non-small cell lung cancer (NSCLC) is the largest subgroup of lung cancer, occurring at a frequency of over 80% of lung cancer cases. In up to 30% of NSCLC patients the oncogenic driver of tumor growth is a constitutively activated EGF receptor (EGFR
Autor:
Ethan Dmitrovsky, Konstantin H. Dragnev, Sarah J. Freemantle, Samuel Waxman, Vincent A. Memoli
Publikováno v:
Cancer Prevention Research. 8:CN05-03
We previously reported that both nuclear retinoic acid receptor (RAR, retinoid) and retinoid X receptor (RXR, rexinoid) agonists can trigger proteasomal degradation of cyclins. This confers check point arrest and repair of carcinogenic DNA damage in
Autor:
John D. Minna, Elvira L. Liclican, Catalina Perdomo, Steven M. Dubinett, Paul Pagano, Linh M. Tran, Kostyantyn Krysan, Teresa Wang, Spira Avrum, Michael C. Fishbein, Jill E. Larsen, Stacy J. Park, Longsheng Hong, Tonya C. Walser, Marc E. Lenburg
Publikováno v:
Cancer Prevention Research. 8:B22-B22
Despite a strong correlation between cigarette smoking and the onset of lung cancer, the prevalence of smoking still remains high. The electronic cigarette (ECIG) is designed to deliver nicotine without combusting tobacco. Since nicotine is widely co